Household transmission of rotavirus in Malawian children with acute gastroenteritis is associated with disease severity

Similar documents
Effectiveness of monovalent rotavirus vaccine in the Philippines 13 th Rotavirus Symposium, 29 Aug 2018, Minsk, Belarus

Vaccines against Rotavirus & Norovirus. Umesh D. Parashar CDC, Atlanta, GA

Value of post-licensure data to assess public health value Example of rotavirus vaccines

Noroviruses. Duncan Steele Bill & Melinda Gates Foundation. Acknowledgements: Ben Lopman and Umesh Parashar, CDC Megan Carey and Julia Bosch, BMGF

Rotavirus vaccine impact on diarrhea associated child mortality, hospital admissions & clinical visits in Bolivia

Rotavirus vaccines: Issues not fully addressed in efficacy trials

Predictors of vaccine virus replication, immune response and clinical protection following oral rotavirus vaccination in Malawian children

GlaxoSmithKline Biologicals Rotarix WHO PACKAGE INSERT. Rotarix TM 1 WHO Package insert

Population effectiveness of the pentavalent and monovalent rotavirus vaccines: a systematic review and meta-analysis of observational studies

Fecal shedding of rotavirus vaccine in premature babies in the neonatal unit

Rotavirus Vaccine Impact and Effectiveness in Armenia and Moldova

Correlates of efficacy for human rotavirus vaccines Value of anti-rotavirus immunoglobulin A antibody concentrations

Rotavirus serotype surveillance: Results and experiences in Tanzania. Adolfine Hokororo. KPA Vaccinology Symposium- 29 th April

Descriptive epidemiology of rotavirus infection in a community in North India

Prevention of Rotavirus Infections. Dr. ANCA DRAGANESCU INBI Matei Bals Bucuresti

Training in Infectious Diseases Modeling. A reflection on vaccination as a disease control measure

How to measure impact of rotavirus vaccination: Opportunities for synergies across Nordic countries?

in control group 7, , , ,

A prospective hospital-based surveillance of Rotaviral Disease in children at the Port Moresby General Hospital, Papua New Guinea. Dr.

Risk factors for symptomatic and asymptomatic norovirus infection in the community

Vaccination with 10-valent pneumococcal conjugate vaccine in infants according to HIV

Burden of Paediatric Rotavirus Gastroenteritis & Potential Impact of Rotavirus Vaccination

Northwestern Health Unit

GSK Medicine: Study No.: Title: Rationale: Study Period Objectives: Indication: Study Investigators/Centers: Research Methods: Data Source:

Impact of Rotavirus Vaccination on Diarrheal Hospitalizations in Children Aged <5 Years in Lusaka, Zambia

Impact of withholding breastfeeding around the time of Rotarix vaccination on the immunogenicity of Rotarix vaccine A Randomized Trial

Rotarix TM. Rotavirus vaccine

Viral Agents of Paediatric Gastroenteritis

Daniel Hungerford 1,2,3,4*, Roberto Vivancos 2,3,4, Jonathan M. Read 3,4,5, Miren Iturriza-Gόmara 1,3, Neil French 1 and Nigel A.

Updates on Rotasiil development

Estimates of the economic burden of rotavirus-associated and all-cause diarrhoea in Vellore, India

Downloaded from:

Can we improve the performance of live oral rotavirus vaccines?

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS

Assessing public health impact through vaccine probe analyses. Robert F. Breiman Emory Global Health Institute Emory University

Core 3: Epidemiology and Risk Analysis

Cost-effectiveness of Monovalent Rotavirus Vaccination of Infants in Malawi: A Postintroduction Analysis Using Individual Patient Level Costing Data

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS

A rotavirus immunisation programme was introduced into the routine childhood immunisation programme from 1 July 2013 for infants aged 2 and 3 months.

Rotavirus. Rotavirus. Vaccine-Preventable Diseases WHO Vaccine-Preventable Diseases Surveillance Standards. Surveillance Standards

ROTAVIRUS VACCINES. Virology

VIRAL GASTRO-ENTERITIS

Country spotlight: Fiji

Rotavirus. Children s Ward Macclesfield District General Hospital.

GSK Medicine: Rotarix (HRV): GlaxoSmithKline Biologicals live attenuated human rotavirus vaccine Study No.: (EPI-ROTA ) Title:

Using A Transmission Dynamic Model Of Rotavirus Infection To Determine The Cost- Effectiveness Of Rotavirus Vaccination In Bangladesh

Dr Michelle Groome MBBCh (Wits) DCH(SA) MScMed (Epi & Biostats) Department of Science and Technology/National Research Foundation: Vaccine

Samir K Saha, Ph.D Child Health Research Foundation Dhaka Shishu Hospital Dhaka, Bangladesh

Rotavirus Infections and Vaccinations in

Rotarix TM. Rotavirus vaccine

Author's personal copy

Gastroenteritis. Information for patients and visitors

Rotavirus Factsheet What you need to know about Rotavirus

Effectiveness of rotavirus vaccination Generic study protocol for retrospective case control studies based on computerised databases

WHO Rotavirus Vaccine Update Dr. Fatima Serhan WHO/FWC/IVB/EPI

Lessons from Rotavirus Vaccine Implementation in the U.S.

Rotarix TM. Rotavirus vaccine. 1 dose (1.5 ml) contains: Live attenuated human rotavirus RIX4414 strain

Norovirus Outbreak in a Children s Hospital. Jennifer Adams, MT, MPH, CIC April 23, 2015

PERINATAL HEPATIDES AND HUMAN IMMUNODEFICIENCY VIRUS (HIV) Pamela Palasanthiran Staff Specialist, Paediatric Infectious Diseases

Monitoring For Rotavirus Serotypes In The Americas. Jon Gentsch

UNIVAC decision support model A universal framework for evaluating vaccine policy options in low- and middle-income countries

NHS public health functions agreement Service specification No.5 Rotavirus immunisation programme

Pthaigastro.org. Drugs Used in Acute Diarrhea: Cons. Nipat Simakachorn, M.D. Department of Pediatrics Maharat Nakhon Ratchasima Hospital.

HEPATITIS C, ACUTE CRUDE DATA. Number of Cases 5 Annual Incidence a LA County 0.05 California b 0.10 United States b 0.68 Age at Diagnosis Mean 38

Jennifer J. Hull 1, Nigel Cunliffe 2, Khuzwayo C. Jere 2,3, Sung-Sil Moon 1, Yuhuan Wang 1, Umesh Parashar 1, Baoming Jiang 1

USING AN INTEGRATED APPROACH TO ASSESS HEPATITIS B VACCINATION AND IMMUNITY AMONG PEOPLE LIVING WITH HIV

Long-term Consistency in Rotavirus Vaccine Protection: RV5 and RV1 Vaccine Effectiveness in US Children,

Rotavirus, the most common cause of severe diarrhea in infants

Hepatitis and pregnancy

Shabir A. Madhi. Progress and Challenges of Immunization Contributing Toward Attaining the MDG Goal to Reduce under-5 Childhood Mortality.

The Cumulative Incidence of HIV Infection in HIVexposed Infants with a Birth Weight of 1500g Receiving Breast Milk and Daily Nevirapine

Infectious Disease Outbreaks in confined spaces

Prevalence of Diarrhoeal Diseases Among Children under Five Years in East African Countries from

Protective Effect of Natural Rotavirus Infection in an Indian Birth Cohort

Roger I. Glass, M.D., Ph.D. Fogarty International Center, NIH Viral Gastroenteritis Unit, CDC

Norovirus. Dr Bhakti Vasant Public Health Physician. Metro South Public Health Unit

Management of MDR TB in special situations. Dr Sarabjit Chadha The Union

Measles: United States, January 1 through June 10, 2011

Effect of Rotavirus Vaccination on Death from Childhood Diarrhea in Mexico

Edwin J. Asturias Associate Director

California 2010 Pertussis Epidemic. Kathleen Winter, MPH Immunization Branch California Department of Public Health

Protecting your baby against rotavirus

Baby Friendly Vaccines

Epidemic Investigation and Management By

GASTROENTERITIS. What you need to know BECAUSE...CARING COMES NATURALLY TO US

Literature Rotavirus vaccines

Sustained Effectiveness of Monovalent and Pentavalent Rotavirus Vaccines in Children

Transmission of Group B Streptococcus in Malawi: A Prospective Cohort Study

CONTROL OF VIRAL GASTROENTERITIS OUTBREAKS IN CALIFORNIA LONG-TERM CARE FACILITIES

Arresting HIV in Malawi prisons

CUMULATIVE PERINATAL HIV EXPOSURE, AUSTRALIA. Date

Jonathan D. Sugimoto, PhD Lecture Website:

Assessing the Evidence for Potential Benefits and Risks of Removing the Age Restrictions for Rotavirus Vaccination

rotavirus; quantitation; real-time polymerase chain reaction

ROTAVIRUS VACCINES FOR AUSTRALIAN CHILDREN: INFORMATION FOR GPS AND IMMUNISATION PROVIDERS

JMSCR Vol 05 Issue 11 Page November 2017

MANAGING ACUTE MALNUTRITION IN INFANTS (MAMI): WHERE ARE WE NOW? Nicki Connell, Emergency Nutrition Advisor, SCUS Date: 19 th October 2016

Transcription:

Household transmission of rotavirus in Malawian children with acute gastroenteritis is associated with disease severity Dr Aisleen Bennett International Rotavirus Symposium, Minsk, Belarus August 2018

Introduction Rotavirus vaccine effectiveness is reduced in low income settings. Any additional effect of vaccine on transmission may improve overall impact RVV: reduction in severe RVGE Disease severity may relate to viral shedding density Symptoms associated with risk of transmission Potential for RVV to impact on infectiousness of rotavirus case

Study aims Investigate risk factors for household rotavirus transmission in Blantyre, Malawi What is the SAR of rotavirus infection from a symptomatic index child to household contacts in Blantyre? What is the SAR of rotavirus disease from a symptomatic index child to household contacts in Blantyre? Is disease severity associated with rotavirus transmission to household contacts?

Control households Random location Contain child frequency age matched to index children Clinical data Stool sample for rotavirus testing (qrt-pcr) Age eligible RV +ve child Questionnaire Severity scoring (Vesikari score) Vaccine status (Health passports) Stool sample: qrt-pcr for rotavirus viral load Blood sample: Serum IgA, HIV testing Household recruitment Surveillance for clinical disease 2 stool samples from HH members Real-time qrt-pcr for rotavirus Intensive cohort 9 stool samples per HH member 28 days follow up 20 months Study Design Diarrhoeal surveillance Children under 5 years with AGE at QECH Clinical data Stool sample for rotavirus testing (EIA)

Methods: analytical Secondary attack rate Infection: proportion of household contacts with >100 copies rotavirus on qrt-pcr Disease: proportion of household contacts with >100 copies rotavirus on qrt- PCR and symptoms of gastroenteritis Comparisons between proportions chi squared tests Predictive factors for transmission for infection and disease Hierarchal conceptual framework Poisson models with an exchangeable correlation matrix (GEE)

Distal susceptibility factors (household level) Household size Toilet type Shared toilet Distance to water Source of water Maternal education Household head education Number of people in household with a salary Has an adult in the house skipped a meal in the last month due to insufficient food? How often does the household have difficulty obtaining the food it needs? Wealth Proximal susceptibility factors (individual contacts) Relationship to child Share room with child Share bed with child Share toilet with child Age of household contact Time spent with child Time spent in house HIV status Primary care giver for child Responsibility for changing nappy Under 5 household contacts only: Rotavirus vaccine status Prematurity Birth weight WHZ WAZ HAZ MUAC Infectiousness Factors (index child) Age Sex HIV exposure HIV infection Prematurity Birth weight Breast feeding Rotavirus vaccine status WHZ WAZ HAZ MUAC Vesikari score Diarrhoea duration (days) Diarrhoea frequency (per day) Vomiting Vomiting frequency Vomiting duration Dehydration Thirst Temperature Outcome Admission Viral load Genotype of rotavirus

Results: Index children Recruitment from Jan 2015 to November 2016 196 symptomatic index children with 705 contacts 55 asymptomatic control children with 144 contacts Characteristics of index children Median age 11.5 months (IQR 8.7, 15.5) 55% males (108/196) 13% HIV exposed (25/196) 99% vaccinated (194/196) Severe disease - median vesikari score of 14 (IQR 12, 16) No significant difference between characteristics of index children and control children

Secondary attack rates Infection Clinical disease >= 100 copy numbers Rotavirus positive clinical disease Study Control X 2 P** Study Control X 2 P** Overall 434/664 (65.4%) 40/144 (27.8%) <0.001 Ϯ 37/701 (5.28) 0/153 (0.0) 0.004 Ϯ

Risk factors for infection in household contacts Variable RR P Value 95% CI Vesikari 1.04 0.007 1.01, 1.07 Age in months 1.00 0.821 1.00, 1.01 Sex Male 0.98 0.788 0.85, 1.13 Log viral copy number 1.01 0.360 0.99, 1.04 Number of adults with salary in household None 1 0.82 0.002 0.72, 0.93 Problems getting food in the past month (%) No Sometimes/often 0.90 0.192 0.76, 1.06 Relationship with child Mother Other adult relative 0.74 0.000 0.64, 0.85 Child contact 0.82 0.000 0.73, 0.91 Muac 1.07 0.006 1.02, 1.14

Risk factors for disease in household contacts Disease IRR P value 95% CI Vesikari score 1.27 0.001 1.09, 1.48 Age in months 1.02 0.396 0.98, 1.06 Log viral copy numbers 1.00 0.897 0.92, 1.10 Toilet type None Simple pit/vip 0.62 0.310 0.24, 1.57 Water toilet 0.34 0.341 0.04, 3.12 Skin pinch Normal Goes back slowly 0.51 0.265 0.16, 1.66 Goes back very slowly 0.93 0.907 0.26, 3.14 Household member age <5 years 5-15 years 0.15 0.001 0.05, 0.48 15-45 years 0.38 0.005 0.19, 0.75 45+ years 0.42 0.400 0.06, 3.13

Conclusions Secondary attack rates for rotavirus infection are high (65%) Attack rates for clinical disease are lower (5%) Increasing disease severity in index children increases the risk of infection and disease in household contacts Vaccination has potential to reduce infectiousness of a vaccinated index child and contribute to herd protection.

Acknowledgements Supervisors Prof Nigel Cunliffe Dr Naor Bar-Zeev Dr Dean Everett Dr Louisa Pollock RotaRITE study team Malawi Ministry of Health staff Patients and participants Collaborators Prof Miren Iturriza-Gomara (UoL) Dr Ben Lopman (CDC) Dr Khuzwayo Jere (UoL) Prof Umesh Parashar (CDC) Dr Virginia Pitzer (Yale School of Public Health)